Global Immune Checkpoint Inhibitors Market Size & Outlook

The global immune checkpoint inhibitors market size was estimated at USD 48,426.3 million in 2023 and is projected to reach USD 154,254.5 million by 2030, growing at a CAGR of 18% from 2024 to 2030.
Revenue, 2023 (US$M)
$48,426.3
Forecast, 2030 (US$M)
$154,254.5
CAGR, 2024 - 2030
18%
Report Coverage
Worldwide

Global immune checkpoint inhibitors market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Global immune checkpoint inhibitors market highlights

  • The global immune checkpoint inhibitors market generated a revenue of USD 48,426.3 million in 2023 and is expected to reach USD 154,254.5 million by 2030.
  • The market is expected to grow at a CAGR (2024 - 2030) of 18% by 2030.
  • In terms of segment, pd-1 accounted for a revenue of USD 35,524.8 million in 2023.
  • Other Types is the most lucrative type segment registering the fastest growth during the forecast period.
  • In terms of region, North America was the largest revenue generating market in 2023.
  • Country-wise, China is expected to register the highest CAGR from 2024 to 2030.

Global data book summary

Market revenue in 2023USD 48,426.3 million
Market revenue in 2030USD 154,254.5 million
Growth rate18% (CAGR from 2024 to 2030)
Largest segmentPd-1
Fastest growing segmentOther Types
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPD-1, PD-L1, CTLA-4, Other Types

Other key industry trends

  • In terms of revenue, the North America accounted for 62.8% of the global immune checkpoint inhibitors market in 2023.
  • By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
  • By country, China is the fastest growing regional market and is projected to reach USD 6,257.7 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Immune Checkpoint Inhibitors Market Companies

Name Profile # Employees HQ Website
BeiGene Ltd ADR View profile 10000 c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, Cayman Islands, KY1-1108 https://www.beigene.com
Shanghai Junshi Biosciences Co Ltd Class H View profile 2568 Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, China, People's Republic of https://www.junshipharma.com
GlaxoSmithKline View profile 10001+ London, England, United Kingdom, Europe http://www.gsk.com
AstraZeneca PLC View profile 89900 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA https://www.astrazeneca.com
Roche View profile 10001+ Basel, Basel-Stadt, Switzerland, Europe http://www.roche.com
Regeneron Pharmaceuticals Inc View profile 13450 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 https://www.regeneron.com
Eli Lilly and Co View profile 43000 Lilly Corporate Center, Indianapolis, IN, United States, 46285 https://www.lilly.com
Bristol-Myers Squibb Co View profile 34100 Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 https://www.bms.com
Merck & Co Inc View profile 72000 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 https://www.merck.com
Sanofi SA View profile 87994 46, avenue de la Grande Armée, Paris, France, 75017 https://www.sanofi.com

Global immune checkpoint inhibitors market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immune checkpoint inhibitors market will help companies and investors design strategic landscapes.


Pd-1 was the largest segment with a revenue share of 73.36% in 2023. Horizon Databook has segmented the Global immune checkpoint inhibitors market based on pd-1, pd-l1, ctla-4, other types covering the revenue growth of each sub-segment from 2018 to 2030.


  • Global Immune Checkpoint Inhibitors Type Outlook (Revenue, USD Million, 2018-2030)
    • PD-1
    • PD-L1
    • CTLA-4
    • Other Types
  • Global Immune Checkpoint Inhibitors Application Outlook (Revenue, USD Million, 2018-2030)
    • Breast Cancer
    • Bladder Cancer
    • Colorectal Cancer
    • Other Applications
    • Lung Cancer
    • Melanoma
    • Cervical Cancer
    • Hodgkin Lymphoma
  • Global Immune Checkpoint Inhibitors Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
    • Hospital Pharmacy
    • Specialty Pharmacy
    • Online Pharmacy

Reasons to subscribe to Global immune checkpoint inhibitors market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Global immune checkpoint inhibitors market databook

  • Our clientele includes a mix of immune checkpoint inhibitors market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of global-level data and insights on the Global immune checkpoint inhibitors market, including forecasts for subscribers. This global databook contains high-level insights into Global immune checkpoint inhibitors market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Global immune checkpoint inhibitors market size, by regions, 2018-2030 (US$M)

Top 10 countries: Immune checkpoint inhibitors market size, 2023 (US$M)

Global immune checkpoint inhibitors market share, by type, 2023 & 2030 (%, US$M)

Immune checkpoint inhibitors market: Opportunity assessment by country

Global immune checkpoint inhibitors market, by region, 2023 (US$M)

Global immune checkpoint inhibitors market size, by regions, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online